Nuvectis Pharma Inc. (NASDAQ: NVCT) has announced the publication of an article titled, “Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors,” in Cancer Research by Scientists from the University of Edinburg. The article highlights the robust activity of NXP900 in preclinical models of Triple-Negative Breast Cancer with Integrin-Linked kinase loss.
NXP900 superior to bosutinib
NXP900 is a highly selective novel SRC/YES1 antagonist developed by Nuvectis that efficiently blocks SRC-mediated activation by blocking both the enzymatic and scaffolding roles of SRC/YES1 kinases without causing immunosuppression.
Professor and Chairperson of Cancer Therapeutics at the Institute of Genetics and Cancer at the Cancer Research UK Edinburgh Centre in Edinburgh, Scotland, Dr. Valerie G. Brunton, Ph.D., conducted the study. Dr. Brunton and his colleagues at the University of Edinburgh illustrated that ILK loss makes TNBC more susceptible to SRC antagonists and that treatment with NXP900 (dubbed “eCF506” in the paper) was better compared to treatment with bosutinib, an authorized multikinase inhibitor that inhibits SRC kinase’s catalytic function. Importantly, NXP900 was proven to be superior to bosutinib in entirely blocking the formation of ILK-knock-out tumors.
Dr. Brunton said, “Our findings are that loss of ILK sensitizes breast cancer to SRC/YES1 inhibitors and that this exposes a therapeutic vulnerability in breast cancer, representing a potential avenue for clinical development. We are enthusiastic about NXP900’s promising activity in in vitro and in vivo models and hope this can pave the way for improved breast cancer treatment.”
NXP900 could be the first SRC/YES1 antagonist
CEO and Founder Ronald Bentsur stated, “We are encouraged by the data reported in the publication reported today. This is the second paper published to date highlighting NXP900’s robust preclinical activity in TNBC, which remains a significant unmet medical need. Moreover, the ILK loss within TNBC represents a potential biomarker-based clinical approach.”
The in vivo findings support the hypothesis that NXP900 could be the maiden SRC/YES1 antagonist to be used to cure solid tumors. The company is testing the drug in a variety of other in vivo models right now, and we’ll use the data to guide future clinical trials.
